GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.67 USD
-0.49 (-1.25%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $38.68 +0.01 (0.03%) 5:42 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.67 USD
-0.49 (-1.25%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $38.68 +0.01 (0.03%) 5:42 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod
by Zacks Equity Research
AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.
Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.
West Pharmaceutical (WST) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.
GSK vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GSK vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab
by Zacks Equity Research
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.
Charles River (CRL) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.
Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.
Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.
PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.
Ecolab (ECL) Q4 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across most of its segments drives its Q4 sales despite business challenges.
Pfizer (PFE) to Ride on COVID Jab & Pill in 2022: What Next?
by Kinjel Shah
Pfizer's (PFE) COVID-19 vaccine and its oral antiviral pill for COVID-19, Paxlovid are expected to generate a combined $54 billion in sales in 2022.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Pfizer, AstraZeneca, Glaxo, Sanofi's and Eli Lilly
by Zacks Equity Research
Pfizer, AstraZeneca, Glaxo, Sanofi¿¿¿s and Eli Lilly are highlighted in this Analyst Blog.
CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.
Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab
by Zacks Equity Research
An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.
Pharma Stock Roundup: PFE, AZN, GSK's Q4 Earnings, FDA Updates for SNY, LLY
by Kinjel Shah
Pfizer (PFE), AstraZeneca (AZN) and Glaxo (GSK) report fourth-quarter results. FDA approves Sanofi's (SNY) new rare blood disorder drug.
AstraZeneca (AZN) Q4 Earnings Beat, COVID Vaccine Drives Sales
by Zacks Equity Research
AstraZeneca (AZN) surpasses fourth-quarter estimates for both revenues and earnings. The company issues 2022 guidance
Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the recovery in sales of new and specialty drugs, and Consumer Healthcare products along with additional revenues from COVID-19 drug, Xevudy.
Vir (VIR) Announces Encouraging Data on COVID-19 Antibody
by Zacks Equity Research
Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.
Can Value Investors Select GlaxoSmithKline (GSK) Stock Now?
by Zacks Equity Research
Is GlaxoSmithKline (GSK) a great pick from the value investor's perspective right now? Read on to know more.
Market Futures Higher Ahead of Opening
by Zacks Equity Research
Market Futures Higher Ahead of Opening
Markets Stampede into the Green; CVS, GSK Beat, YUM Mixed
by Mark Vickery
Seeing our economy gaining in growth is a good reason for investors to become a little less risk-averse.
Glaxo (GSK) Beats Earnings and Revenues Estimates in Q4
by Indrajit Bandyopadhyay
Glaxo (GSK) beats earnings as well as revenues estimates in the fourth quarter of 2021. Stock down.
Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven fourth-quarter sales. The performance of vaccines during Q4 remains to be seen.